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INTRODUCTION 
Global health is entering a time of funding uncertainty. While the previous decade saw significant 
increases in support for global health programs,1 many are concerned that funding from donor 
governments, private aid organizations, and foundations – the traditional sources of assistance for 
global health –  may not grow further or may even decline in the aftermath of an international financial 
crisis and mounting efforts to control public expenditures and debt.2,3 In addition, advocates see 
ongoing missed opportunities in advancing global health-relevant technologies (including drugs, 
vaccines and diagnostics) due to a reliance on financing mechanisms that do not necessarily provide 
enough research and development-related incentives for addressing the health concerns of low- and 
middle-income countries.4,5,6 Therefore, in order for global health programs to maintain and expand 
their impact in the coming years, there is increasing interest in identifying ways to supplement 
traditional sources of health assistance, and adopting new methods of financing global health programs, 
research, and development to complement existing approaches.7 The issue has been placed on the 
agenda at the upcoming Group of Twenty (G-20) Summit in France later this year, with Bill Gates 
scheduled to deliver a report to G-20 leaders addressing financing for development.8   
 
For these reasons, there is growing attention to “innovative financing mechanisms,” a broad category of 
novel approaches to raising and spending funds for global health. While exact definitions of innovative 
financing may differ, a key dimension of such mechanisms is that they have the potential to supplement 
and expand on the impact of existing and traditional channels of health assistance by tapping into new 
resources or squeezing out more impact from the resources that are available.9 As such, many see 
innovative financing mechanisms as tools that could help to bridge some of the global health financing 
and technological innovation gaps experienced by low- and middle-income countries.   
 
While the U.S. government has been at the forefront of designing and implementing some innovative 
financing mechanisms, it has been less likely to embrace others.  The Obama Administration has 
championed innovation for development, emphasizing the positive impacts that new approaches and 
technologies can have on global health and other areas of development. For example, “innovating for 
results” has been included as one of the four key implementation components of the Global Health 
Initiative (GHI), the Administration’s six-year, proposed $63 billion effort to implement a comprehensive 
global health strategy,10 and support for “game-changing innovations” was named an agency priority by 
the U.S. Agency for International Development (USAID).11  At the same time, a number of existing 
innovative financing mechanisms do not have the support of the U.S. government for reasons that range 
from concerns about their cost-effectiveness and perceived feasibility, to policy and legal challenges 
posed by a need for making upfront, multi-year funding obligations, changes in tax law, or other issues. 
So, while U.S. interest in innovative approaches to global health may be growing, it is unclear whether or 
how this momentum will translate into increased support for innovative financing mechanisms, 
especially in light of important policy and legal issues raised by some of them and the potential trade-
offs that may be involved. For example, the innovative financing mechanism currently attracting the 
most support from European governments and others in the lead up to the G-20 is the Financial 
Transaction Tax, a mechanism the U.S. does not support.12  
 
To help assess these issues, this paper first defines, and provides a classification system for, different 
types of innovative financing mechanisms for global health. It next presents an inventory of innovative 
financing mechanisms that are currently in use or proposed and examines the status of U.S. government 
participation in these mechanisms.  Finally, it explores potential policy barriers and opportunities for 
further U.S. government engagement.   
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DEFINING INNOVATIVE FINANCING  
 
The concept of innovative financing is complex, 
with no single, widely accepted definition currently 
in use. Rather, multiple definitions have been 
proposed over time ranging in how expansively the 
concept is defined, the categories of mechanisms 
included, and other factors (see Box 1).  For 
example, some definitions are relatively narrow in 
scope, focusing only on those mechanisms which 
tap into new revenue sources, while others include 
a broader set of mechanisms, reaching beyond the 
generation of new revenue sources to encompass 
tools intended to stimulate research and 
development (R&D) or those designed to make 
more efficient and effective use of existing 
funds.13,14,15,16,17 Furthermore, some definitions 
focus on global health specifically, while others 
apply the term more broadly to include new 
financing approaches for climate change, 
education, and other areas of international 
development in addition to global health. 
 
Despite the lack of a single definition, several 
common elements run through these multiple 
concepts of innovative financing.  For example, 
innovative financing mechanisms are typically 
presented in contrast to “traditional” mechanisms for raising and delivering aid.  “Traditional” 
mechanisms for global health financing include direct bilateral and multilateral assistance provided by 
government donors, or funds channeled through private philanthropy; innovative approaches to funding 
attempt to raise funds from other sources or catalyze financing in unique, non-traditional ways. 
Likewise, “traditional” methods of financing innovation and R&D for global health rely on private 
industry investments subject to existing, standard market incentives or governmental research grants, 
while innovative approaches might attempt to shift market incentives toward greater investment in 
global health R&D or stimulate public-private research partnerships.  In this way, innovative financing 
mechanisms are meant to add value by raising additional funds and/or make existing funds go farther.  
They are meant to be complementary to existing, traditional approaches, but are not designed to 
displace or replace them. 
MECHANISM CATEGORIES 
For the purpose of this paper, we build upon prior definitions to identify three main categories of 
innovative financing mechanisms for global health. These are described below, and are contrasted with 
more “traditional” financing mechanisms. These categories are further divided into sub-categories based 
on their approach, as listed in Box 2 and described in Methodology.  
 
 Novel funding mechanisms18 – Traditional sources of funding for global health programs are bilateral 
or multilateral official development assistance (ODA) given by donor governments, and private 
donations made through foundations and charities.  In contrast, novel funding mechanisms are 
BOX 1. DEFINITIONS OF “INNOVATIVE FINANCING” 
 
The term “innovative financing” has been defined in 
different ways by different organizations. Three prior 
definitions for the term are:   
 
 “[A]ny financing approach that helps to generate 
additional development funds…enhance the efficiency 
of financial flows…[or] make financial flows more 
results-oriented.” 
-The World Bank13 
 
 “[N]ew sources of development financing [that] are 
closely linked to global public goods, and complement 
conventional official development assistance.”  
-The Leading Group on Innovative Financing for 
Development14 
 
 “[N]on-traditional applications of overseas 
development assistance, joint public-private, or private 
mechanisms and flows that 1) support fund-raising by 
tapping new sources…, or 2) deliver financial solutions 
to development problems on the ground.”  
-The High Level Taskforce on Innovative Financing 
for Health Systems15 
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those that aim to tap into or free up new funds beyond these traditional channels or to make more 
aid more “economically efficient” (e.g., by making it more rapidly available).  Examples of novel 
funding mechanisms include: the use of bonds to “front-load” funding, implementation of new tax 
schemes to raise additional funding for global health, debt relief channeled to global health, and 
loan guarantees or risk pooling vehicles that seek to catalyze private investments in health projects 
in developing countries. 
 
 Mechanisms to stimulate innovation, research, and development (R&D)19 – Traditionally, financial 
support for innovation, research, and product development for global health issues has relied on 
public research grants (e.g., funding provided to researchers and innovators by government 
agencies like the U.S. National Institutes of Health or the U.S. Agency for International Development) 
and standard market incentives for private-sector investment (e.g., private pharmaceutical 
companies pursuing R&D projects based on expected market potential).  Research grants can be 
considered a source of “push” funding that drives innovations through the R&D pipeline, while the 
incentives provided by future market sales can be considered a source of “pull” financing for R&D.  
By contrast, innovative mechanisms in this category use novel “push” and “pull” strategies to 
accelerate or scale-up the development and production of innovations and technologies relevant to 
global health (such as medicines, vaccines, and diagnostics), as well stimulate greater distribution 
and better access to them. They are intended to go beyond what traditional grant or market 
incentive mechanisms can do for example, by serving to alter standard market incentives (e.g., 
through increasing the incentives to invest in R&D) or providing public research funding in non-
traditional ways (e.g., through tax credits, prizes, or based on the health impact of innovations). 
 
 Mechanisms incentivizing performance and/or results20 – Traditionally, donors have provided global 
health aid by paying for inputs (e.g., the infrastructure, training, commodities, and supplies needed 
to implement health programs), using funding that is not explicitly conditional on subsequent 
program performance nor on the ultimate impact on health. Innovative mechanisms in this 
category, by contrast, aim to provide funding that is conditional on performance or results in order 
to improve outcomes and impacts. They aim to alter incentives faced by recipient governments and 
organizations, or individual beneficiaries, in such a way as to improve performance, achieve better 
results, or to have individuals adopt healthier behaviors compared with traditional input-based, 
non-conditional financing approaches. Examples of performance or results-based mechanisms 
include aid that is contingent on explicit criteria (i.e., recipients must meet certain quality or other 
benchmarks to merit consideration for assistance) or aid distributed according to measurable health 
outcomes or impacts rather than health inputs.  
TYPES OF PUBLIC/PRIVATE INVOLVEMENT 
Innovative financing mechanisms may also be characterized according to level of public and private 
sector involvement; depending on their construct and approach, mechanisms may be classified as 
belonging to one of the following three types: “Public,” “Private,” or “Mixed” mechanisms.  
 
“Public” mechanisms are those that require governmental involvement to be implemented. Examples of 
“Public” mechanisms include those requiring changes to tax policy (such as a Financial Transactions Tax), 
or in regulations or legislation (such as the U.S. Federal Drug Administration’s Priority Review Voucher). 
“Private” mechanisms are those that do not require governmental support or involvement to function, 
such as voluntary consumer-based contribution programs and Impact Investing. “Mixed” mechanisms 
feature combined public and private sector involvement, although the role of the public sector across 
these mechanisms can vary. Examples of “Mixed” mechanisms include those that use public funds to 
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back credit guarantees or finance risk pooling to catalyze private investments, or an Advance Market 
Commitment backed by public funds that are used to stimulate private research, development, or 
distribution of health technologies.  
METHODOLOGY 
To identify innovative financing mechanisms for global health for this analysis, we conducted a literature 
review and interviewed key experts. Our review encompassed both mechanisms that are currently 
operational (defined as those that are functioning in at least one country, even if only in a pilot or trial 
phase) and those that remain proposals yet to be implemented. Not all mechanisms identified were 
included in the final list; to make determinations about which mechanisms to exclude or include we 
considered the following factors: the complementarity/additionality of each mechanism to traditional 
aid approaches, the actual or potential relevance of each mechanism to global health (as opposed to 
other development objectives), and the attention given to the mechanism in the literature and by 
experts. As such, the list of mechanisms is meant to be representative, but not entirely exhaustive of all 
innovative financing options available.   
 
After determining the final list, we placed each mechanism into one of the three mechanism categories 
outlined above. When a given mechanism spanned more than one category, we assigned it to the 
category we considered most directly captured its primary approach and purpose. Within each category, 
we further sub-categorized the list of mechanisms by type of approach, identifying five sub-categories of 
novel funding mechanisms, two sub-categories among mechanisms that stimulate innovation/R&D 
mechanisms, and two sub-categories among those that incentivize performance and results (see Box 2.)  
 
BOX 2. Classification Scheme for Innovative Financing Mechanisms for Global Health  
 
Novel funding mechanisms  
 Sub-categories: 
 Directing private investment, catalyzing private investments in health 
 Consumer-based funding, tapping into voluntary contributions from consumers  
 Front-loading funds, leveraging long-term pledges of assistance to generate 
funding in the short-term 
 Re-directing credits or debts, leveraging credits and debts for financing  
 New taxes or levies, new funds generated by applying taxes to select transactions 
 
Mechanisms to stimulate innovation, research & development (R&D)  
 Sub-categories: 
 “Push” mechanisms, financing or other incentives provided to innovators up front, 
which reduce risks or costs of R&D 
 “Pull” mechanisms, financial rewards or other incentives provided to innovators 
for progress or completion of research, development, or scale-up of production, 
which enhance market opportunities 
 
Mechanisms incentivizing performance/results 
 Sub-categories:  
 Supply side, meant to incentivize governments and health care providers 
 Demand side, meant to incentivize patients/clients of health care system   
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Each mechanism was selected based on its representation of an innovative financing approach, and any 
given mechanism may have more than one implementation example. For instance, there are multiple 
organizations that support a risk pooling or credit guarantee approach to catalyzing private investments, 
including the U.S. Overseas Private Investment Corporation (OPIC), USAID’s Development Credit 
Authority (DCA), the Pledge Guarantee for Health (PGH), and the World Bank’s Multilateral Investment 
Guarantee Agency (MIGA). Rather than list these each of these instruments individually, they are 
included under the common umbrella of “Risk Pooling/Credit Guarantees” (within the sub-category of 
“directing private investments,” under the category of novel financing mechanisms). Similarly, there are 
multiple examples of “Results-Based Aid” approaches (within the sub-category “supply side results-
based mechanisms” under the category mechanism incentivizing performance/results), from the 
benchmark eligibility restrictions placed on Compact funding provided through the Millennium 
Challenge Corporation to Global Fund grant continuations that are contingent on meeting minimum 
performance levels.  
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FINDINGS 
Findings are presented in two parts.  First, the characteristics of the mechanisms are summarized and 
described. Then, the nature of U.S. engagement with the mechanisms is summarized and discussed.  
MECHANISMS BY CLASSIFICATION AND KEY CHARACTERISTICS 
In all, 31 innovative financing mechanisms for global health across the three main categories were 
identified for inclusion. Table 1 summarizes the counts of mechanisms by category and sub-category, 
while Table 2 lists each of the mechanisms, its type of public/private involvement, and operational 
status.  Additional details and further descriptions of each of the mechanisms are presented in the 
attached Appendix tables. 
 
As Table 1 shows, the 31 
mechanisms were comprised of 
14 novel financing mechanisms, 
12 mechanisms to stimulate 
innovation, R&D, and 5 
mechanisms incentivizing 
performance/results.  
 
As Table 2 shows, twelve 
mechanisms were characterized 
as “Public,” fourteen were 
“Mixed,” public-private efforts, 
and five were characterized 
strictly as “Private” (see Table 1). 
All five of the “Private” 
mechanisms were in the novel 
financing category; this category 
also had six “Public” and three “Mixed” mechanisms (see Table 2). Among the 12 mechanisms to 
stimulate innovation, R&D, half were “Public” and half “Mixed.” Finally, among the 5 mechanisms 
incentivizing performance/results, one was “Public” and four “Mixed.”  
 
Twenty-one of the mechanisms are currently operational, while 10 remain at the proposal stage.  Those 
that are operational are: 10 of the 14 novel funding mechanisms, 7 of the 12 innovation and R&D 
mechanisms, and 4 of the 5 incentivizing results/performance mechanisms (see Table 2). 
 
Although not a focus of this report, estimates of the potential for these innovative financing 
mechanisms to generate additional revenue, or leverage existing funding streams to make them go 
further, range significantly (see Appendix). 
  
TABLE 1. INNOVATIVE FINANCING MECHANISMS FOR GLOBAL HEALTH: 
Counts By Category and Sub-category  
Mechanisms by Category and Sub-Category # 
   Novel financing mechanisms  14 
 Directing private investment 3 
 Voluntary consumer-based funding  3 
 Front-loading funds 1 
 Re-directing credits or debts 4 
 New taxes or levies 3 
  
   Mechanisms to stimulate innovation, R&D 12 
 “Push” mechanisms 5 
 “Pull” mechanisms 7 
  
   Mechanisms incentivizing performance/results 5 
 Supply side 3 
 Demand side 2 
  
  
TOTAL NUMBER OF MECHANISMS 31 
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TABLE 2. INNOVATIVE FINANCING MECHANISMS FOR GLOBAL HEALTH:  
Overview with Key Characteristics 
Mechanism Category 
   Mechanism subcategory 
              Mechanism Name 
Type of Public/Private 
Involvement Status 
Novel financing mechanisms    
   Directing private investment   
 Exchange Traded Funds (ETFs) Private Operational 
 Impact Investing Private Operational 
 Risk Pooling/Credit Guarantees Mixed Operational 
   Voluntary consumer-based funding    
 Mobile Phone Solidarity Contribution Private Operational 
 Consumer Product-Based Contribution Private Operational 
 Travel Purchase Solidarity Contribution Private Operational 
   Front-loading funds   
 International Finance Facility (IFF) Mixed Operational 
   Re-directing credits or debts   
 Buy-downs Mixed Operational 
 Debt Forgiveness for Health Public Operational 
 De-tax Public Proposed 
 IMF1 Gold  Sales/Special Drawing Rights  Public Proposed 
   New taxes or levies   
 Airline Ticket Tax Public Operational 
 Financial Transaction Tax (FTT) Public Proposed 
 Tobacco Solidarity Tax Public Proposed 
 Mechanisms to stimulate innovation, R&D   
   “Push” mechanisms   
 Patent Fees/“Green Intellectual Property” Public Proposed 
 Patent Pools Mixed Operational 
 Pooled Funding Mixed Proposed 
 Product Development Partnerships (PDPs) Mixed Operational 
 R&D Tax Credits Public Operational 
   “Pull” mechanisms   
 Advance Market Commitment (AMC) Mixed Operational 
 Medicines Subsidy Mixed Operational 
 Health Impact Fund Public Proposed 
 Milestone R&D Incentives Mixed Proposed 
 Priority Review Voucher Public Operational 
 End-Product Prizes Mixed Operational 
 Patent Review Voucher  Public Proposed 
Mechanisms incentivizing performance/results   
   Supply side results-based mechanisms   
 Cash-on-Delivery (COD) Aid Public Proposed 
 Performance-Based Financing (PBF) Mixed Operational 
 Results-Based Aid (RBA) Mixed Operational 
   Demand side results-based mechanisms   
 Conditional Cash Transfers (CCT) Mixed Operational 
 Vouchers Mixed Operational 
Summary Total number of mechanisms: 31  
Mechanisms by Type of Public/Private Involvement  Count 
 Public      12 
 Private      5 
 Mixed      14 
  
Mechanisms by Status     Count 
 Operational     21 
 Proposal      10 
1 IMF = International Monetary Fund.  
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U.S. GOVERNMENT 
PARTICIPATION 
The “Public” and “Mixed” 
mechanisms were examined to 
assess whether the U.S. 
government is engaged with 
them either as a funder or 
implementer (“Private” 
mechanisms do not require 
government involvement to 
function and therefore are 
excluded from this portion of the 
analysis).  This examination 
focused on those mechanisms 
that are currently operational, 
though implications of these 
findings for proposed 
mechanisms were considered, 
and are discussed below.  
Findings are summarized in 
Tables 3 and 4.  
 
The findings show the U.S. 
government has demonstrated a 
greater willingness to engage 
with mechanisms that have 
private sector elements, such as 
the “Mixed” mechanisms of Risk 
Pooling/Credit Guarantees and 
Product Development 
Partnerships, but has been less 
likely to engage with purely 
“Public” mechanisms, especially 
those requiring legislative or 
regulatory changes leading to tax 
increases (such as a Financial 
Transaction Tax) or up-front, 
multi-year financial obligations 
(such as an International Finance 
Facility).  
 
Among the 26 “Public” or 
“Mixed” mechanisms, 16 are 
operational, and of these, the 
U.S. government currently 
participates in or implements 9 
(see Table 4). U.S. support was 
TABLE 3. INNOVATIVE FINANCING MECHANISMS FOR GLOBAL HEALTH:  
U.S. Government Participation 
Mechanism Category 
   Mechanism subcategory 
              Mechanism Name 
Engagement/ Participation 
from U.S. Government 
Novel financing mechanisms   
   Directing private investment  
 Exchange Traded Funds (ETFs) N/A1 
 Impact Investing N/A1 
 Risk Pooling/Credit Guarantees Yes 
   Voluntary consumer-based funding   
 Mobile Phone Solidarity Contribution N/A1 
 Consumer Product-Based Contribution N/A1 
 Travel Purchase Solidarity Contribution N/A1 
   Front-loading funds  
 International Finance Facility (IFF) No 
   Re-directing credits or debts  
 Buy-downs Yes 
 Debt Forgiveness for Health No 
 De-tax N/A2 
 IMF3 Gold  Sales/Special Drawing Rights  N/A4 
   New taxes or levies  
 Airline Ticket Tax No 
 Financial Transaction Tax (FTT) No 
 Tobacco Solidarity Tax No 
 Mechanisms to stimulate innovation, R&D  
   “Push” mechanisms  
 Patent Fees/“Green Intellectual Property” No 
 Patent Pools Yes 
 Pooled Funding No 
 Product Development Partnerships (PDPs) Yes 
 R&D Tax Credits No6 
   “Pull” mechanisms  
 Advance Market Commitment (AMC)5 No 
 Medicines Subsidy5 No 
 Health Impact Fund No 
 Milestone R&D Incentives No 
 Priority Review Voucher Yes 
 End-Product Prizes No7 
 Patent Review Voucher  Yes 
Mechanisms incentivizing performance/results  
   Supply side results-based mechanisms  
 Cash-on-Delivery (COD) Aid No 
 Performance-Based Financing (PBF) Yes 
 Results-Based Aid (RBA) Yes 
   Demand side results-based mechanisms  
 Conditional Cash Transfers (CCT) Yes 
 Vouchers Yes 
1 Public or Mixed mechanisms only, not applicable (N/A) for Private mechanisms.   
2 De-Tax only applicable where value-added tax (VAT)-based tax system is used; U.S. does 
not have a VAT-based tax system. 
3 IMF = International Monetary Fund. 
4 IMF Gold Sales and Special Drawing Rights listed as N/A due to multilateral nature of IMF 
governance; the U.S. share of IMF Executive Board vote is 16.76%. 
5 AMC (the current pneumococcal vaccine AMC) and Medicines Subsidy (the current 
Affordable Medicines Facility-malaria, AMFm) are considered “pull” mechanisms because 
they are designed to increase the uptake of vaccines and malaria medicines, respectively; 
see Methods. 
6 The US has supported R&D tax credits in some cases (e.g. “orphan drugs”, bioterrorism), 
but no such credits have supported for R&D for developing country-specific health issues.  
7 The America COMPETES Act (H.R. 5116) gives agencies authority to use prizes for 
innovation, but no global health-related prizes have been supported to date. 
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more common among the “Mixed” mechanisms compared to “Public” ones: eight of the 12 operational 
“Mixed” mechanisms are currently implemented or supported (the exceptions are the International 
Finance Facility, the Advance Market Commitment, the Medicines Subsidy, and End-Product Prizes), 
while only one of the four “Public” mechanisms is supported or implemented by the U.S. (the Priority 
Review Voucher, a U.S. government initiative, is the exception).  
 
TABLE 4. PUBLIC AND MIXED INNOVATIVE FINANCING MECHANISMS FOR GLOBAL HEALTH:  
Counts by Key Characteristics and U.S. Government Participation 
Mechanisms by Key Characteristics # 
   Public 12 
 Operational 4 
 Of which, supported by U.S. Government  1 
 Proposed 8 
 Of which, supported by U.S. Government 0* 
  
   Mixed 14 
 Operational 12 
 Of which, supported by U.S. Government 8 
  
 Proposed 2 
 Of which, supported by U.S. Government 0 
  
  
   Total Number of Public and Mixed Mechanisms 26 
 Of which, supported by U.S. Government 10 
*One proposed mechanism, the De-tax, is not applicable to the U.S. tax system and therefore not under consideration in 
the U.S.  
 
As noted above, the U.S. government has shown a greater tendency to engage with “Mixed” 
mechanisms over purely “Public” ones. Table 5 lists the mechanisms that already have some level of U.S. 
government support and includes illustrative examples of U.S. engagement.   
 
Looking at those mechanisms in the proposal stage, if a similar pattern held U.S. involvement might 
favor those mechanisms that avoid new taxes or up-front multi-year financial obligations. Of the 10 
“Public” or “Mixed” mechanisms that remain and are in the proposal stage, four are tax-based: one (the 
De-tax) requires a Value-Added Tax (VAT) system; the U.S. does not have a VAT-based tax system. Three 
others (the Financial Transaction Tax, Tobacco Solidarity Tax, and Patent Fees/“Green Intellectual 
Property”) derive funds through imposing taxes or fees.  
 
Three other proposed mechanisms to stimulate innovation, R&D (Pooled Funding, Milestone-based 
Funding, and Health Impact Fund) have some similarities to operational mechanisms that the U.S. 
already supports (such as “Product Development Partnerships” and “Patent Pools”), though specific 
concerns with each of these proposals – from their cost-effectiveness to political and financial feasibility 
– would have to be considered prior to any decisions to support them. Another proposed innovation, 
R&D mechanism – Patent Review Vouchers – was originally proposed by the government and therefore 
has some level of support already.21  
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TABLE 5. EXAMPLES OF U.S. GOVERNMENT ENGAGEMENT IN INNOVATIVE FINANCING MECHANISMS FOR 
GLOBAL HEALTH * 
Category 
   Sub-category 
 Mechanism 
Public or 
Mixed Examples of U.S. Government Engagement 
Novel financing mechanisms 
   Re-directing credits or debits 
 Risk Pooling/Credit 
 Guarantees Mixed 
The U.S. Overseas Private Investment Corporation (OPIC) provided $2.4B of 
financing and insurance and USAID’s Development Credit Authority (DCA) 
provided approximately $500M in loan guarantees in 2010, though in both cases 
only a small proportion were in support of health-related projects.22,23 
 Buy-downs Mixed 
The U.S. Centers for Disease Control and Prevention (CDC) has participated in a 
multi-party buy-down of credit to Nigeria linked to achievement of polio 
vaccination targets.24,25  
Mechanisms to stimulate innovation, R&D 
   “Push” mechanisms 
 Patent Pools Mixed The U.S. National Institutes of Health has offered royalty free licenses for several proprietary HIV drug patents to the UNITAID Medicines Patent Pool.26,27 
 Product 
 Development 
 Partnerships (PDPs) 
Mixed In 2009 contributions from USAID and NIH to PDPs totaled $45 million, comprising approximately 9 percent of total PDP funding.28  
   “Pull” mechanisms 
 Priority Review 
 Voucher (PRV) Public 
Authorizing legislation for the PRV passed by Congress in 2007, first PRV 
awarded by the FDA in 2009.29,30,31   
Mechanisms incentivizing performance/results 
   Supply side results-based mechanisms 
 Performance-
 Based Financing 
 (PBF) 
Mixed 
USAID has incorporated PBF into a limited number of its global health programs, 
often on a pilot basis, in countries such as Rwanda, Egypt, Haiti, and  
Honduras.32,33  
 Results Based Aid 
 (RBA) Mixed 
The U.S. Millennium Challenge Corporation (MCC) utilizes an RBA approach, 
directing funding only to countries that qualify based on particular benchmarks 
outlined in advance (MCC health sector funding comprises approximately 2 
percent of its total compact funding).34  
   Demand side results-based mechanisms 
 Conditional Cash 
 Transfers (CCT) Mixed 
USAID has implemented CCT programs for maternal health programs in 
countries such as India.35  
 Vouchers Mixed USAID-supported voucher programs targeting maternal health services have been implemented in countries such as Pakistan.36 
* These are the ten operational Public and Mixed mechanisms among those included in the analysis that the U.S. currently supports or 
implements. Private mechanisms and Proposed mechanisms are not included in this table.  These are illustrative examples, and do not fully 
describe all U.S. government support for each mechanism. 
 
The International Monetary Fund (IMF) novel financing mechanisms (IMF Gold Sales/Special Drawing 
Rights) would have to be initiated and implemented through the IMF governance apparatus, of which 
the U.S. is a part.  While a single IMF member could not unilaterally require or prohibit adoption of one 
of these proposals, some countries do have more influence than others; for example, the U.S. has the 
largest voting share of any country on the IMF Executive Board (currently controlling 16.76% of all 
votes).37  
 
Finally, “Cash on Delivery Aid,” a proposed supply side results-based mechanism, would involve an 
upfront, multi-year funding obligation, and therefore U.S. support for the mechanism could face the 
same obstacles as similar mechanisms not currently supported by the U.S., such as the Advance Market 
Commitment or the International Finance Facility.38   
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POLICY CONSIDERATIONS FOR U.S. ENGAGEMENT 
As noted above, this analysis finds that nine of the 16 operational Mixed or Public Mechanisms are 
currently supported or implemented by the U.S. government, while seven are not; another ten have 
been proposed and are not currently supported or implemented by the U.S. government.  This section 
gives an overview of policy considerations and potential barriers to further engagement with innovative 
financing mechanisms by the U.S. 
MECHANISMS WITH CURRENT ENGAGEMENT 
For those nine mechanisms the U.S. government already supports or implements, policy considerations 
going forward center on whether or not the U.S. should increase or decrease its level of engagement 
with the mechanisms. For example, while the U.S. has in the past implemented Buy-downs for global 
health, there may be additional, unrealized opportunities to further U.S. goals through more extensive 
use of the Buy-down approach.  Likewise, while Performance-based Financing and Vouchers have been 
incorporated as elements of U.S. programs in a limited number of countries, a question remains about 
whether or not wider (or narrower) application of these mechanisms is desirable. Similar policy debates 
around the proper level of U.S. engagement apply across all of the mechanisms the U.S. government 
supports.39 
MECHANISMS WITH POTENTIAL ENGAGEMENT 
For those mechanisms with which the U.S. government does not currently engage, multiple factors 
could influence the decision to newly support a given mechanism. In some cases, policymakers may 
question the cost-effectiveness of an innovative mechanism in comparison to more traditional 
alternatives. For example, by law, the U.S. government is currently restricted from supporting the 
Affordable Medicines Facility for Malaria (AMFm), an example of a Medicines Subsidy, “pending 
compelling evidence of success” for the AMFm approach.40 Other factors that could influence policy 
decisions on engagement with innovative financing mechanisms include: the applicability of the 
mechanism to or consistency with U.S. goals and objectives in global health, the viability of introducing 
the mechanism in the broader economic and political context, the amount and type of governmental 
involvement needed, and any legal, budgetary, or regulatory barriers that could limit or prevent the U.S. 
from supporting a given mechanism.   
COMMON POLICY BARRIERS 
As summarized above, among the 26 “Public” or “Mixed” mechanisms, 16 are operational, and of these, 
the U.S. government currently participates in or implements nine (see Table 4). U.S. support is more 
common for “Mixed” mechanisms compared to “Public” ones.  For the 14 operational and proposed 
mechanisms without U.S. support, which the U.S. could potentially engage with*, we identified two 
policy barriers that commonly apply, over and above the other potential considerations of cost-
effectiveness, impact, and viability, discussed above. These common policy barriers include a need to 
either 1) change U.S. tax policy (the case with five mechanisms) or 2) provide an upfront, multi-year 
funding commitment (the case with three mechanisms). These common barriers are summarized in 
Table 6 and discussed further below. 
 
Among the other eight mechanisms that are not subject to either of these two policy barriers are some 
that share important similarities to those the U.S. already implements or supports. This could signal 
                                                          
* Though a Proposed mechanism, the Patent Review Voucher was counted as having U.S. support given that it is a U.S. proposal. This leaves 16 
other “Public” or “Mixed” mechanisms the U.S. does not support.  Of these, two are N/A for considerations of U.S. government participation for 
purposes of this report: the De-tax and IMF Gold Sales/SDR mechanisms.  
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that, setting aside potential cost-effectiveness and other considerations, they might face fewer policy 
hurdles to gain U.S. government support. For example, the Pooled Funding mechanism has similarities 
to the Patent Pool and Product Development Partnerships mechanisms to which the U.S. government 
already contributes. The Patent Review Voucher, which is similar in approach to the Priority Review 
Voucher, remains a proposed mechanism but is in fact a U.S. initiative and therefore already enjoys a 
level of government support. 
 
Table 6 lists all of the mechanisms (operational and proposed) that the U.S. government does not 
currently support, along with the applicability of these policy barriers to each. 
 
Changes in Tax Policy. Among the mechanisms that would require changes in tax policy are the: Airline 
Ticket Tax, Financial Transaction Tax, R&D Tax Credits, Patent Insurance/“Green IP,” and Tobacco 
Solidarity Tax. For example, an Airline Ticket Tax (which at least six other national governments have 
already implemented in support of the international drug purchasing fund UNITAID)41 would require 
legislation to institute a new mandatory tax added to the sale of airline tickets in the U.S. Similarly, 
implementing a Financial Transaction Tax (which over 40 countries, including the United Kingdom, have 
already implemented in some form at a domestic level)42 would require a new law that authorized such 
a tax in the U.S. A bill seeking to implement such a tax was introduced into the House of Representatives 
and referred to committee in 2010 (H.R. 5783, the “Investing in Our Future Act of 2010”), though the bill 
did not progress beyond that stage.43 In addition, the current political climate is not favorable to 
additional taxes.   
 
 
 
TABLE 6. PRIMARY POLICY BARRIERS TO INNOVATIVE FINANCING MECHANISMS FOR GLOBAL HEALTH 
NOT CURRENTLY IMPLEMENTED OR SUPPORTED BY THE U.S.*  
Category    
   Mechanism Name 
Requires 
Change(s) in 
Tax Policy 
Requires Upfront 
Multi-Year Funding 
Commitment 
Other 
Potential 
Barriers 
Novel Financing Mechanisms     
   International Finance Facility  X  
   Debt Forgiveness for Health    X 
   Airline Ticket Tax X   
   Financial Transaction Tax X   
   Tobacco Solidarity Tax X   
Mechanisms to Stimulate Innovation, R&D    
   Patent Insurance/“Green IP” X   
   Pooled Funding   X 
   R&D Tax Credits X   
   Advanced Market Commitment  X  
   End-Product Prizes   X 
   Medicines Subsidy   X 
   Health Impact Fund   X 
   Milestone-based R&D Incentives    X 
Mechanisms Incentivizing Performance/Results    
Cash-on-Delivery Aid  X  
* Includes Operational and Proposed mechanisms. Not included in the table are: IMF Gold Sales/SDRs (which would require 
multilateral policy action through the IMF Board) and De-Tax (which requires a VAT-based tax system, not present in U.S.). The Patent 
Review Voucher is a mechanism proposed by U.S. government and therefore not included in this table.   
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Upfront, Multi-Year Funding Commitments. Other innovative mechanisms require upfront, multi-year 
funding commitments, i.e. obligating funding now for expenditures in future fiscal years. Mechanisms 
facing this barrier include the Advance Market Commitment, the International Finance Facility, and 
Cash-on Delivery Aid, each of which is predicated on long-term promises of support, with donors having 
to provide future year expenditure commitments in advance, sometimes without even knowing for sure 
how large the future budgetary outlays will be.44 U.S. agencies are typically prevented from making long-
term discretionary spending commitments and obligations with U.S. federal funding and must instead 
ask, and receive Congressional approval for, their discretionary funds each year. Therefore, discretionary 
budget commitments for future years – sometimes five, ten, or more years out from the present – as 
are required by these mechanisms are largely prohibited, as specified by anti-deficiency laws dating back 
to the nineteenth century and codified under Title 31 of the United States Code, which specifically 
prohibits obligating “payment of money before an appropriation is made.”45  
 
While obligating future expenditures that have not yet been appropriated is prohibited, Congress has 
the ability to appropriate funds for multiple years in advance through a process known as “advance 
appropriations,” which the Office of Management and Budget defines as “appropriations of new budget 
authority that become available one or more fiscal years beyond the fiscal year for which the 
appropriation act was passed.”†46 The advantage of such a construct is that a funding amount for a 
future year would not be “scored” – that is, counted – against the current fiscal year budget but would 
rather count against the year in which the appropriations legislation indicates it is to be made 
available.47 Therefore, any advance-appropriated funds would be “budget neutral” for the current year. 
At the same time, because an advance appropriation would then be scored against the budget in the 
future year in which it is obligated, it would count against the agency’s budget ceiling in that year and 
therefore restrict its budgetary flexibilities. While the advance appropriations option has been exercised 
by Congress in the past in the context of several domestic programs,48 this budgetary technique has not 
been utilized in the context of innovative financing mechanisms, so policymakers would have to weigh 
carefully the trade-offs between the risks and benefits of this approach, such as the potential 
implications for budget flexibility in future years.49   
SUMMARY AND CONCLUSIONS 
Greater attention is now being paid to innovative financing mechanisms and the role they could play in 
maintaining and expanding the impact of global health programs. This growing interest is in part due to 
worries about the availability and sustainability of global health assistance made through traditional 
channels, especially given an environment of fiscal constraint prevalent in the wake of the recent global 
economic crisis. While not expected to serve as a replacement for traditional health financing, such 
mechanisms may help to supplement existing funding, increase its effectiveness, and incentivize 
innovation in targeted areas.    
 
This analysis has summarized and categorized existing information on prominent innovative financing 
mechanisms for global health. Overall, 31 mechanisms were identified across three main categories: 
novel funding mechanisms, mechanisms to stimulate innovation and R&D, and mechanisms incentivizing 
                                                          
† The U.S. government has, on two recent occasions, provided multi-year “pledges” of support for global health – 
to the Global Fund in 2010 for three years and the GAVI Alliance in 2011 for three years – but pledges are not 
equivalent to appropriations and future fiscal year funding for these pledges will still have to be authorized and 
appropriated by the U.S. Congress. 
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performance and/or results. These categories were further organized into sub-categories, identifying 
mechanisms that could be grouped together based on similarities in approach.  
 
The U.S. government supports some of these innovative financing mechanisms but not others, in 
particular demonstrating a tendency to support mechanisms with “Mixed” – public-private – elements 
such as government funds used to catalyze private investments in health programs or R&D, over wholly 
government-based “Public” mechanisms such as new taxes. Among those mechanisms that are not 
already supported by the government, two main policy barriers emerge: the need to make changes in 
U.S. tax policy for some mechanisms, and the need for upfront, multi-year funding commitments to 
support others. While there are policy options available for overcoming these barriers, the risks and 
benefits of each potential policy course (over and above the policymakers’ assessment of each 
mechanism’s cost-effectiveness and political viability) should be given careful consideration going 
forward. 
 
As the U.S. and other donors prepare for the G-20 Summit in France and the Fourth High Level Forum on 
Aid Effectiveness in Korea soon after, increasing attention will be placed on the role of innovative 
financing mechanisms, from the Financial Transaction Tax proposal that has received the most attention 
thus far and support from some donors (although not the U.S.), to mechanisms that include some level 
of private sector engagement and which have received support from the U.S. in the past. Consideration 
of the merits and effectiveness of expanding the use of these mechanisms, and careful examination of 
the roles they could play in light of growing pressure on aid budgets, will be important for the U.S. and 
other donors to assess.  Moreover, the potential for such mechanisms to generate additional new 
revenue or make existing funding streams go further vary significantly and in part depend on the extent 
to which they might be adopted and level of commitment given to them.  Ultimately, even if such 
mechanisms do gain more traction in the U.S. and elsewhere, it will be important to remember that the 
need for traditional health aid will persist. 
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